Skip to content

Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma

Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00634777
Acronym
pet
Enrollment
239
Registered
2008-03-13
Start date
2007-01-31
Completion date
2012-01-31
Last updated
2011-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Squamous Cell Carcinoma

Keywords

HNSCC biopsy-proven, T1-T4 oral cavity oropharynx hypopharynx larynx, N+ scheduled for an organ preservation treatment protocol based on concomitant, chemoradiation

Brief summary

Patients with advanced head and neck squamous cell carcinoma (HNSCC) may benefit from organ-preservation treatment based on combination of chemotherapy and radiotherapy without compromising disease-free and overall survival. In patients with initially advanced regional disease, there is controversy about the place of routine planned lymph node neck dissection after chemoradiotherapy, especially in responding patients without clinically invaded residual lymph nodes. There is uncertainty about the lymph nodes status after chemoradiation because the structural imaging modalities (CT, MRI) lack sensitivity and specificity : small positive lymph nodes are not detected, and residual large lymph nodes can be sterilized ( ghosts nodes with no sign of viable tumor cells at histopathology). Despite the absence of evidence based on prospective study, in numerous institutions currently, head and neck surgeons are quite reluctant to operate on for neck dissection patients with a complete clinical and radiological response following chemoradiation. Metabolic imaging of tumors using PET and the glucose analog FDG has proven effective in head and neck SCC, especially after treatment to differentiate disease progression from radiation-induced inflammation.1 Several studies have shown that the metabolic response could predict the presence or absence of residual tumor cells in the primary tumor as well as the probability of relapse .2-4 Conflicting results have been reported on the use of PET to predict the pathological nodal status after chemoradiation, with negative predictive values ranging from 14 % to 100 %.5,6 Discrepancies observed might be due to the fact that PET was performed at variable time points after the end of radiotherapy. Ideally, PET should be performed as late as possible so that tumor regrowth can begin and become detectable, increasing the sensitivity of the procedure.

Detailed description

\- The primary objective is to assess the negative predictive value (NPV) of PET as a single examination in correctly predicting the absence of remaining invaded lymph nodes after chemoradiotherapy for advanced HNSCC. Secondary objectives include : * The evaluation of the suitability of a wait and see approach without neck dissection in patients considered as complete responders ( based on clinical evaluation and imaging assessment including PET : all these diagnosis tools should be negative to consider a patient as a complete responder); this suitability will be estimated using the negative predictive value of the overall assessment of a complete response including PET-FDG but also the clinical evaluation and imaging. * The evaluation of the ability of PET-FDG to correctly predict remaining pathologically invaded lymph nodes (PPV) after chemoradiotherapy for advanced HNSCC in patients with a postchemoradiation positive PET a (and who will therefore be considered with less than a complete regional or locoregional response and who will undergo at least neck dissection.

Interventions

OTHERpet scan

pet scan

Sponsors

Jules Bordet Institute
CollaboratorOTHER
University of Liege
CollaboratorOTHER
Rennes University Hospital
CollaboratorOTHER
Nantes University Hospital
CollaboratorOTHER
Gustave Roussy, Cancer Campus, Grand Paris
CollaboratorOTHER
University Hospital, Paris
CollaboratorOTHER
Poitiers University Hospital
CollaboratorOTHER
University Hospital, Toulouse
CollaboratorOTHER
University Hospital, Rouen
CollaboratorOTHER
University Hospital, Montpellier
CollaboratorOTHER
Central Hospital, Nancy, France
CollaboratorOTHER
Centre Oscar Lambret
CollaboratorOTHER
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Biopsy-proven HNSCC * Clinical stage: unpreviously treated T1-T4 oral cavity, oropharynx, hypopharynx, larynx * Only patients suitable for at least a neck dissection after chemoradiotherapy will be included. Consequently, inclusion criteria are thus : T1-T4 , N1 N2a, N2b N2c N3 M0. * Patient scheduled for an organ preservation treatment protocol based on concomitant chemoradiation (induction chemotherapy is allowed if this approach is followed by concomitant chemoradiation)

Design outcomes

Primary

MeasureTime frame
Efficacy of PET scan in evaluation of patient with HNSCC regionally advanced12 weeks after chemoradiation

Countries

Belgium

Contacts

Primary ContactMarc Hamoir, MD
marc.hamoir@uclouvain.be+3227641974
Backup ContactSandra Schmitz, MD
schmitz_sany@hotmail.com+32427641976

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026